Experts Answer Ovarian Cancer Questions | Memorial Sloan Kettering





The interactive transcript could not be loaded.



Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Sep 21, 2010

To learn more about ovarian cancer treatments, please visit http://www.mskcc.org/ovariancancer
Like us on Facebook: http://www.facebook.com/sloankettering
Follow us on Twitter: http://twitter.com/sloan_kettering

Ovarian cancer experts answer a variety of questions about managing chemotherapy side effects, genetic testing of patients and their relatives, improving early detection of the disease, and the development of targeted therapies such as PARP inhibitors to enhance the effectiveness of existing chemotherapies.

{partial transcript}

The next question is: how do we deal with preventing side effects such as neuropathy, which has proved to be a difficult problem in ovarian cancer? Some of our most effective agents, like Taxols, Taxotere, platinums do cause neuropathy.

We spend a lot of time working on this and producing trials looking at the use of carboplatin instead of cisplatin to try and lower this rate. There is still work to do there.

There hasn’t been a chemotherapy drug or an agent specifically to treat or prevent neuropathy.

If you have any questions, we are dealing with some comments that Dr. Barakat made about symptoms that might be present in the months or years prior to an ovarian cancer diagnosis. We hear a lot of patients are very frustrated about that. They come to us with a diagnosis of stage three ovarian cancer and they look back and feel as though symptoms were not addressed appropriately.

We do encourage people to go to their doctors with persistent symptoms over the course of a few weeks, but it is not easy…


When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...